Short Interest in Affimed (NASDAQ:AFMD) Grows By 11.7%

Affimed (NASDAQ:AFMD) saw a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 219,400 shares, an increase of 11.7% from the March 31st total of 196,400 shares. Based on an average trading volume of 91,100 shares, the days-to-cover ratio is presently 2.4 days. Currently, 1.7% of the company’s shares are short sold.

Institutional Investors Weigh In On Affimed

Several institutional investors and hedge funds have recently modified their holdings of AFMD. EWA LLC acquired a new position in Affimed during the 4th quarter worth approximately $89,000. abrdn plc purchased a new stake in shares of Affimed during the fourth quarter valued at approximately $130,000. Vestal Point Capital LP acquired a new position in shares of Affimed during the fourth quarter worth $341,000. Finally, BNP Paribas Financial Markets boosted its stake in shares of Affimed by 39.9% in the fourth quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock valued at $357,000 after purchasing an additional 163,162 shares during the period. Hedge funds and other institutional investors own 30.82% of the company’s stock.

Analyst Upgrades and Downgrades

AFMD has been the topic of several research analyst reports. HC Wainwright raised their target price on shares of Affimed to $10.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. StockNews.com started coverage on Affimed in a report on Tuesday, January 2nd. They set a “sell” rating for the company. Wells Fargo & Company reduced their target price on Affimed from $30.00 to $25.00 and set an “overweight” rating on the stock in a report on Monday, April 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a research note on Monday, April 1st. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Affimed presently has a consensus rating of “Moderate Buy” and an average target price of $45.00.

Affimed Stock Up 3.1 %

Shares of NASDAQ AFMD opened at $5.03 on Monday. The stock has a fifty day moving average price of $5.46 and a 200 day moving average price of $5.02. The company has a current ratio of 3.25, a quick ratio of 3.23 and a debt-to-equity ratio of 0.11. Affimed has a 12-month low of $2.23 and a 12-month high of $11.10. The company has a market cap of $76.61 million, a P/E ratio of -0.60 and a beta of 2.05.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.